Ligand mediated drug targeting pdf

A tumor targeting peptide, GE11, was used to conjugate onto the surface of doxorubicin encapsulated phospholipid micelles, leading to enhanced cellular uptake and cytotoxicity in vitro and highly accumulation in the tumors in vivo. 18 PDF An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy. Review Receptor-Mediated Drug Delivery Systems Targeting to Glioma Shanshan Wang, Ying Meng, Chengyi Li, Min Qian and Rongqin Huang * Received: 25 September 2015; Accepted: 24 November 2015; Published: 28 December 2015 Academic Editors: Subramanian Tamil Selvan, Wolfgang J. Parak and Pablo del Pino Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry Rationale: "Active targeting" based on the ligand -target affinity is a common strategy to precisely deliver nanoparticle (NP) imaging probes or drug carriers to the diseased tissue. However, such ligand -mediated active targeting inevitably takes place with prerequisite "passive targeting", driven by the enhanced Peptide ligand-mediated targeted drug delivery of nanomedicines. Zhuxuan Jiang, J. Guan, +1 author C. Zhan Published 29 January 2019 Biology, Chemistry Biomaterials science Targeted drug delivery is emerging as a promising strategy to achieve better clinical outcomes. Several reviews exist on ligand-targeted drug delivery systems, some particularly dealing with the chemical and biochemical aspect of targeted constructs (Kapoor et al., 2019; Srinivasarao and Low, 2017). In this re-view, we focus on the biological barriers that limit tissue-tar-geted therapy and categorize targeting strategies based on The effective treatment of glioma is largely hindered by the poor transfer of drug delivery systems across the blood-brain barrier (BBB) and the difficulty in distinguishing healthy and tumorous cells. In this work, for the first time, an The diverse moieties investigated so far as targeting ligands include carbohydrates (e.g., galactose), monoclonal antibodies (e.g., anti-Her2, anti-EGFR), peptides (e.g., Arg-Gly-Asp or RGD), proteins (e.g., lectins, transferrin), vitamins (e.g., vitamin D), and aptamers (e.g., RNA aptamers against HIV glycoprotein). View chapter Purchase book The strategy for identifying tumor-targeting ligands and developing ligand-mediated targeted therapy is shown in Figure 1. Researchers have used in vivo affinity selection of phage libraries to identify peptides that interact with the molecules found on endothelia in tumors [ 34 , 36 ]. Generally, active targeting and passive targeting are the main targeting strategies for targeted drug delivery. In active targeting the drug can be specifically delivered into target cells by binding ligands (which have overexpressed receptors on the surface of the target cells) on the drug formulations surface. We had previously reported the screening and discovery of a novel peptide ligand against EGFR named GE11. It was shown to bind . × Close Log In. Log in with Facebook Log in with Google. or. Email. Password. Remember me on this computer. or reset password. Enter the Download Free PDF. Several approved ligand-targeting agents are in clinical trials involving patients with COVID-19, including the IL-6-targeting drug siltuximab (NCT04329650 and NCT04330638), the VEGFA-targeting The targeting mechanisms, synthesis methods and targeting characteristics of glycosylation-modified drug delivery systems we